Cat. No.: HY-101625

Copy Link Print Information

Recilisib

(Synonyms: ON 01210)

45 Cited Publications

Customer Review

Based on 45 publication(s) in Google Scholar

Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 334969-03-8
Formula: C₁₆H₁₃ClO₄S
Molecular Weight:336.79

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Recilisib Chemical Structure

CAS No.: 334969-03-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (45)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells^[1].

IC₅₀ & Target^[1]

PI3K

All Akt Isoforms :

All PI3K Isoforms :

In Vitro

Recilisib (up to 50 μM) shows a normal distribution of cells throughout the cell cycle, with a slight reduction in the number of cells in S-phase at 50 μM. Continuous exposure of Recilisib (100 μM) does not result in cell death. Recilisib treatment does not inhibit the colony forming potential of human bone marrow cells. Recilisib provides dose dependent protection of human bone marrow cells at all three doses of IR. Recilisib activates the phosphorylation of AKT and GSK3α/β in HFL cells. Recilisib increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib treatment in combination with radiation alters the MAPK signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Recilisib (500 mg/kg) significantly increases the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice. Recilisib in combination with radiation reduces CFU numbers in mice, but the Recilisib-treated mice consistently retain a capability to form differentiated colonies. Recilisib treated mice have a progenitor cell population that is never completely depleted by radiation exposure^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 334969-03-8
Appearance Solid
Molecular Weight 336.79
Formula C₁₆H₁₃ClO₄S
Color White to off-white
SMILES

O=C(O)C1=CC=C(/C=C/S(=O)(CC2=CC=C(Cl)C=C2)=O)C=C1
Synonyms

ON 01210
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (45)

All Cell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Phytomedicine

Dendrobin A inhibits gastric cancer: Mechanistic insights supported by integrated evidence. [Abstract]

2025 Nov:147:157215. PMID: 40913985
Phytomedicine

Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways. [Abstract]

2025 Apr:139:156464. PMID: 39970856

Recilisib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Apr:139:156464. [Abstract]

Recilisib significantly reversed BRU-induced suppression of lipid metabolism in 143B, U2OS cells.
Phytomedicine

Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. [Abstract]

2024 Dec:135:156022. PMID: 39284270

Recilisib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec:135:156022. [Abstract]

Recilisib partially reversed the proliferation inhibitory effect of HA in RBE and HuccT1 cells.

Recilisib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec:135:156022. [Abstract]

Recilisib indeed elevated the protein expression of P-mTOR (Ser2448), P-PI3K (Tyr607), and P-AKT (S473) following HA-induced inhibition PI3K-AKT-mTOR activator recilisib reversed the effect of HA on ICC.
Phytomedicine

Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in macrophages to reduce atherosclerosis in ApoE-/- mice. [Abstract]

2023 Apr:112:154684. PMID: 36738477
Phytomedicine

Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway. [Abstract]

2022 Sep:104:154323. PMID: 35858516
J Pharm Anal

Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma. [Abstract]

2023 May;13(5):463-482. PMID: 37305788

Recilisib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):463-482. [Abstract]

Recilisib (10 μM) activated the PI3K/AKT pathway (via recilisib), leading to an increased HCC cell viability in the cotreatment group compared to the Rk3 only group.

Recilisib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):463-482. [Abstract]

Recilisib (10 μM) increased the protein expression of CDK4, cyclin D1 and P62, as well as decreased the protein expression of Bax, c-PARP and LC3II/LC3I in HepG2 and HCC-LM3 cells with 100 μM Rk3.
J Transl Med

Hispidulin suppresses osteosarcoma by directly targeting FABP4 to disrupt lipid metabolism and inhibit the PI3K/AKT pathway. [Abstract]

2025 Oct 7;23(1):1062. PMID: 41057878
Int J Biol Macromol

A polysaccharide from Grifola frondosa fruit body induces HT-29 cells apoptosis by PI3K/AKT-MAPKs and NF-κB-pathway. [Abstract]

2020 Mar 15:147:79-88. PMID: 31923503

Recilisib purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2020 Mar 15:147:79-88. [Abstract]

Measurement of ERK1/2 and NF-κB p65. Effect of GFP-A and Recilisib (activator of Akt) (10 μmol/L) on the expression of phosphorylated ERK1/2 in HT-29 cells. Cells are treated with 180 μg/mL GFP-A in the presence or absence of Recilisib for different durations of time.
Cell Prolif

MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2. [Abstract]

2024 Nov;57(11):e13700. PMID: 38924190
Cell Mol Neurobiol

Inhibiting PI3K/Akt-Signaling Pathway Improves Neurobehavior Changes in Anti-NMDAR Encephalitis Mice by Ameliorating Blood-Brain Barrier Disruption and Neuronal Damage. [Abstract]

2023 Oct;43(7):3623-3637. PMID: 37314618
Lipids Health Dis

MG-132 activates sodium palmitate-induced autophagy in human vascular smooth muscle cells and inhibits senescence via the PI3K/AKT/mTOR axis. [Abstract]

2024 Sep 4;23(1):282. PMID: 39232759
J Ethnopharmacol

Pharmacological potential of gardoside in anxiety: Behavioral and molecular evidence. [Abstract]

2026 Sep 15:368:121836. PMID: 42106019
J Ethnopharmacol

Elucidation of the mechanisms and therapeutic effects of Sini Decoction on anxiety induced by forced swimming stress in mice. [Abstract]

2026 Sep 15:368:121766. PMID: 42044778
J Ethnopharmacol

Methanol extract of Artemisia argyi against influenza a virus via inhibition of PI3K-AKT pathway activation. [Abstract]

2026 Mar 1:358:120973. PMID: 41317814
J Ethnopharmacol

Huang Bai Jian Pi decoction alleviates diarrhea and represses inflammatory injury via PI3K/Akt/NF-κB pathway: In vivo and in vitro studies. [Abstract]

2022 Jun 28:292:115212. PMID: 35331876
J Agric Food Chem

PI3K-Mediated Regulation of Glycogen Metabolism To Facilitate Tomato chlorosis Virus Transmission by Bemisia tabaci MED. [Abstract]

2025 Jul 23;73(29):18176-18185. PMID: 40626897
Biochem Pharmacol

ATF5 activates LPAR5 to enhance macrophage pro-inflammatory responses to exacerbate rheumatoid arthritis. [Abstract]

2026 May:247:117804. PMID: 41690415
Biochem Pharmacol

Sappanone A, a potential natural inhibitor of PI3K, alleviates metabolic dysfunction-associated steatohepatitis in experimental models. [Abstract]

2025 Sep 4;242(Pt 3):117305. PMID: 40914217
Biochem Pharmacol

TEA domain transcription factor 3 suppresses aortic and left ventricular remodeling via transcriptional activation of PDZ domain containing 1. [Abstract]

2025 Sep 10;242(Pt 2):117329. PMID: 40939874
Inflammopharmacology

Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice. [Abstract]

2025 Apr;33(4):2165-2178. PMID: 40063187
Drug Des Devel Ther

Exploring the Therapeutic Potential of FSGTC for Osteoarthritis: A Comprehensive Study Combining Nested Case Analysis, Network Pharmacology, and Experimental Validation. [Abstract]

2025 Jun 17:19:5123-5141. PMID: 40546656
Int Immunopharmacol

Cbl-b inhibited CD4+ T cell activation by regulating the expression of miR-99a/miR-125b. [Abstract]

2023 Feb:115:109677. PMID: 36634415
mBio

The swine acute diarrhea syndrome coronavirus spike protein promotes syncytial formation via upregulation of cellular cholesterol synthesis. [Abstract]

2025 Aug 13;16(8):e0097625. PMID: 40586601
Sci Rep

Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway. [Abstract]

2023 Aug 11;13(1):13072. PMID: 37567936
J Cell Mol Med

Modified Qianghuo Shengshi Decoction Ameliorates Osteoarthritis via Inhibiting PI3K/Akt Pathway-Related Ferroptosis. [Abstract]

2025 Jul;29(13):e70691. PMID: 40586853
J Cell Mol Med

Tumour necrosis factor-α promotes BMHSC differentiation by increasing P2X7 receptor in oestrogen-deficient osteoporosis. [Abstract]

2020 Dec;24(24):14316-14324. PMID: 33169524
Biomedicines

Quercetin Ameliorates Comorbid Insomnia in Diarrhea-Predominant Irritable Bowel Syndrome via the PI3K/AKT/NF-κB Signaling Pathway. [Abstract]

2026 Mar 17;14(3):692. PMID: 41898339
Biol Trace Elem Res

Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. [Abstract]

2024 Feb;202(2):701-712. PMID: 37156991
J Cell Commun Signal

Structural maintenance of chromosome protein 1A exacerbates liver fibrosis by enhancing hepatic stellate cell activation and extracellular matrix synthesis via laminin subunit gamma 2 activation. [Abstract]

2026 Feb 23;20(1):e70067. PMID: 41737731
Naunyn Schmiedebergs Arch Pharmacol

Ononin induces ferroptosis in colorectal cancer cells via the PI3K/AKT/Nrf2 pathway to enhance anti-cancer immunotherapy. [Abstract]

2025 Jul 8. PMID: 40627200
J Cell Physiol

FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K/AKT pathway. [Abstract]

2024 Jun;239(6):e31267. PMID: 38558303
J Cell Commun Signal

Lysine demethylase 5A promotes prostate adenocarcinoma progression by suppressing microRNA-330-3p expression and activating the COPB2/PI3K/AKT axis in an ETS1-dependent manner. [Abstract]

2022 Dec;16(4):579-599. PMID: 35581421
J Pharm Pharmacol

Targeting the PI3K/AKT signaling pathway with PNU120596 protects against LPS-induced acute lung injury. [Abstract]

2024 Nov 4;76(11):1508-1520. PMID: 39288376
Parasit Vectors

Ac-HSP20 regulates autophagy and promotes the encystation of Acanthamoeba castellanii by inhibiting the PI3K/AKT/mTOR signaling pathway. [Abstract]

2024 Aug 19;17(1):347. PMID: 39160562
Toxicol Appl Pharmacol

Chrysin enhances sunitinib sensitivity in renal cell carcinoma by inducing ferroptosis via targeting PI3K/Akt/GPX4 pathway. [Abstract]

2025 Aug 21:117531. PMID: 40848919
Cell Biol Int

Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma. [Abstract]

2022 Sep;46(9):1519-1529. PMID: 35731168
Mol Cell Endocrinol

Stanniocalcin2 inhibits the epithelial-mesenchymal transition and invasion of trophoblasts via activation of autophagy under high-glucose conditions. [Abstract]

2022 May 1:547:111598. PMID: 35157929
Food Chem Toxicol

Mechanistic insights into AKT1/GSK3β/CD36 axis regulation in ZLY06-induced hepatic lipid metabolism dysfunction and protective intervention via AKT activation strategies. [Abstract]

2025 Oct:204:115628. PMID: 40633829
BMC Anesthesiol

The expression of kappa-opioid receptor promotes the migration of breast cancer cells in vitro. [Abstract]

2021 Aug 30;21(1):210. PMID: 34461834
Tissue Cell

Liensinine induces autophagy and apoptosis in hepatocellular carcinoma via reactive oxygen species-mediated inhibition of the PI3K/AKT/mTOR pathway. [Abstract]

2026 Jun 12:103:103696. PMID: 42314534
Neurosci Lett

Inhibiting specificity protein 1 attenuated sevoflurane-induced mitochondrial stress and promoted autophagy in hippocampal neurons through PI3K/Akt/mTOR and α7-nAChR signaling. [Abstract]

2023 Jan 18:794:136995. PMID: 36464148
Dev Biol

Autophagy participates in germline cyst breakdown and follicular formation by modulating glycolysis switch via Akt signaling in newly-hatched chicken ovaries. [Abstract]

2022 Jul;487:122-133. PMID: 35525303
SSRN

2025 Apr 4.
Research Square Print

2023 Jan 13.
Environ Toxicol

Acylglycerol kinase promotes the stemness of nasopharyngeal carcinoma cells by promoting β-catenin translocation to the nucleus through activating PI3K/Akt pathway. [Abstract]

2020 Dec;35(12):1299-1307. PMID: 32652857

Recilisib purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2020 Dec;35(12):1299-1307. [Abstract]

FaDu cells with AGK overexpression is treated with the PI3K inhibitor LY294002, and Cal27 cells with AGK knockdown is treated with PI3K activator Recilisib (50 μM). The inhibitory effect of LY294002 and promoting effects of Recilisib on PI3K/Akt signaling is confirmed by Western blot analysis.

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (59.38 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9692 mL

14.8460 mL

29.6921 mL

5 mM

0.5938 mL

2.9692 mL

5.9384 mL

10 mM

0.2969 mL

1.4846 mL

2.9692 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (5.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

PI3-kinase assays are performed using exponentially growing HFL-1 or freshly harvested murine bone marrow cells that are treated with increasing concentrations of Recilisib Sodium for 2 hours and then irradiated with 10 Gy IR. These cells are then returned to the incubator for 2 to 24 hours and lysed in HEPES pH 7.5 lysis buffer. PI-3K is immunoprecipitated using an anti-PI3 Kinas polyclonal antibody for 2 hours at 4°C. Protein A/G PLUS-Agarose is incubated with immunoprecipitates for 8-16 hours at 4°C and the resulting immunoprecipitates washed with twice HEPES pH 7.5 lysis buffer and once with the kinase buffer (20 mM Tris pH 7.5, 1mM EGTA, 10mM MgCl₂, 2 mM DTT, 0.01% NP-40). L-α-Phosphatidylinositol (12.5 mM) and ATP (10 µM) are added to the kinase buffer (60 µL per sample) and incubated at 30°C for 30 minutes. The reaction is stopped by addition of 100 µL of 1N HCl and extracted by addition of 200 µL CHCl₃/CH₃OH (1:1). The extracted samples are vortexed, centrifuged and the lower organic phases containing phospholipids are dried at 27°C for 2 hours. The dried samples are resuspended in 10 µL of PI-4-P standard (0.5 mL CHCl₃, 0.5 mL CH₃OH, 2.5 µL HCl) and spotted on TLC plates (VWR). The spotted plate is subjected to thin layer chromatography in CHCl₃/CH₃OH/NH4OH (40:40:15). The TLC plate is dried and subjected to autoradiography.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

For cytotoxicity assays, cells (1.0×10⁵ cells/mL HPGM) are treated with various concentrations of Recilisib Sodium or vehicle without radiation treatment for 2 or 24 hours. The cells are washed and plated into methocult using gridded dishes. The total number of colony forming units (CFUs) is determined 14 days post-plating by microscopic observation using an Olympus IMT-2 microscope.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kang AD, et al. ON01210.Na (Ex-RAD) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9692 mL	14.8460 mL	29.6921 mL	74.2302 mL
	5 mM	0.5938 mL	2.9692 mL	5.9384 mL	14.8460 mL
	10 mM	0.2969 mL	1.4846 mL	2.9692 mL	7.4230 mL
	15 mM	0.1979 mL	0.9897 mL	1.9795 mL	4.9487 mL
	20 mM	0.1485 mL	0.7423 mL	1.4846 mL	3.7115 mL
	25 mM	0.1188 mL	0.5938 mL	1.1877 mL	2.9692 mL
	30 mM	0.0990 mL	0.4949 mL	0.9897 mL	2.4743 mL
	40 mM	0.0742 mL	0.3712 mL	0.7423 mL	1.8558 mL
	50 mM	0.0594 mL	0.2969 mL	0.5938 mL	1.4846 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Recilisib

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Cysteine Targeted Covalent Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Immunology/Inflammation Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Recilisib

All Akt Isoforms

All PI3K Isoforms

Biological Activity

Chemical Information

Publications (45)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Recilisib Related Classifications

HY-101625 Related Classifications